IRIS - Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi dell’Insubria.

IRInSubria - Institutional Repository Insubria
IRInSubria raccoglie, conserva, documenta e dissemina le informazioni sulla produzione scientifica dell'Università degli Studi dell’Insubria anche ai fini della valutazione della ricerca.

AGENO, WALTER
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 62.963
EU - Europa 25.999
AS - Asia 18.799
SA - Sud America 2.243
Continente sconosciuto - Info sul continente non disponibili 955
AF - Africa 347
OC - Oceania 30
Totale 111.336
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 62.006
IT - Italia 12.203
SG - Singapore 6.126
UA - Ucraina 4.102
CN - Cina 3.813
TR - Turchia 2.855
VN - Vietnam 2.493
HK - Hong Kong 2.177
SE - Svezia 1.878
DE - Germania 1.861
BR - Brasile 1.841
IE - Irlanda 1.241
GB - Regno Unito 1.136
FR - Francia 1.018
FI - Finlandia 975
RU - Federazione Russa 862
CA - Canada 423
BD - Bangladesh 314
IN - India 295
MX - Messico 247
AR - Argentina 126
NL - Olanda 121
JP - Giappone 115
AT - Austria 108
ES - Italia 101
NG - Nigeria 98
IQ - Iraq 95
PL - Polonia 94
ZA - Sudafrica 83
EC - Ecuador 66
CO - Colombia 64
ID - Indonesia 63
PK - Pakistan 54
EU - Europa 53
JM - Giamaica 52
SA - Arabia Saudita 51
BE - Belgio 48
CR - Costa Rica 44
VE - Venezuela 43
MY - Malesia 41
UZ - Uzbekistan 39
AE - Emirati Arabi Uniti 38
LT - Lituania 36
CZ - Repubblica Ceca 35
MA - Marocco 34
CL - Cile 31
PH - Filippine 31
TT - Trinidad e Tobago 27
GT - Guatemala 25
HN - Honduras 25
NI - Nicaragua 25
AU - Australia 24
EG - Egitto 24
JO - Giordania 23
KE - Kenya 23
PY - Paraguay 23
CH - Svizzera 21
SV - El Salvador 20
DZ - Algeria 19
RO - Romania 19
NP - Nepal 18
MD - Moldavia 17
TN - Tunisia 17
UY - Uruguay 17
BO - Bolivia 16
PT - Portogallo 16
TW - Taiwan 16
IR - Iran 15
PE - Perù 14
PR - Porto Rico 14
DK - Danimarca 13
GR - Grecia 13
IL - Israele 13
KR - Corea 12
KZ - Kazakistan 12
TH - Thailandia 12
AL - Albania 11
BB - Barbados 11
EE - Estonia 11
GP - Guadalupe 9
HU - Ungheria 9
LB - Libano 9
PS - Palestinian Territory 9
OM - Oman 8
SN - Senegal 8
AZ - Azerbaigian 7
BS - Bahamas 7
CI - Costa d'Avorio 7
MK - Macedonia 7
NO - Norvegia 7
BA - Bosnia-Erzegovina 6
BG - Bulgaria 6
DO - Repubblica Dominicana 6
QA - Qatar 6
RS - Serbia 6
AM - Armenia 5
ET - Etiopia 5
NZ - Nuova Zelanda 5
AO - Angola 4
CG - Congo 4
Totale 110.336
Salva come PNG Salva come JPEG
Città #
Milan 8.560
Fairfield 7.202
Ashburn 5.385
Woodbridge 4.800
San Jose 4.711
Houston 3.581
Jacksonville 3.309
Singapore 3.213
Seattle 2.817
Wilmington 2.639
Cambridge 2.463
Ann Arbor 2.425
Chandler 2.237
Hong Kong 2.143
Council Bluffs 1.973
Dallas 1.634
Izmir 1.398
Princeton 1.354
Dublin 1.230
The Dalles 985
Dearborn 962
Boardman 837
Beijing 706
Dong Ket 683
Rome 681
Chicago 678
Nyköping 664
Lauterbourg 639
Santa Clara 433
Los Angeles 427
San Diego 412
Ho Chi Minh City 400
New York 385
San Mateo 308
London 266
Ogden 263
Hanoi 246
Helsinki 228
São Paulo 219
Como 190
Washington 189
Guangzhou 184
Phoenix 178
Mexico City 155
Munich 153
Düsseldorf 139
Orem 138
Hefei 129
Redmond 125
Nanjing 106
North Bergen 105
Nuremberg 98
Tokyo 97
Shanghai 93
Abuja 92
Frankfurt am Main 90
Toronto 90
Brooklyn 88
Kocaeli 88
Atlanta 87
Buffalo 86
Verona 86
Montreal 85
Kunming 84
Salt Lake City 84
San Francisco 84
Chennai 83
Norwalk 79
Warsaw 78
Hangzhou 76
Columbus 75
Philadelphia 72
Denver 69
Tianjin 64
Boston 62
Shenzhen 62
Stockholm 62
Amsterdam 60
Nanchang 59
Jinan 58
Haiphong 57
Manchester 55
Rio de Janeiro 55
Turku 55
Da Nang 54
Miami 53
Tampa 52
Naples 50
Belo Horizonte 46
Elk Grove Village 46
Johannesburg 46
Zhengzhou 46
Brasília 44
Vienna 44
Detroit 41
Las Vegas 40
Brussels 39
Kilburn 39
Falls Church 38
Fuzhou 35
Totale 78.513
Salva come PNG Salva come JPEG
Nome #
Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: a Delphi analysis of experts 413
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis 328
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery 321
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes 318
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study 315
Warfarin interactions with antibiotics in the ambulatory care setting 302
Abdominal obesity and the risk of recurrent deep vein thrombosis 301
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study 298
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 285
Optimal treatment duration of venous thrombosis 282
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature 282
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment 279
Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. A systematic review 277
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism 277
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. 276
A case report and literature review of portal vein thrombosis associated with Cytomegalovirus infection in immunocompetent patients 275
ABO blood group and vascular disease: an update 270
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism 269
Risk of recurrence of unusual site venous thromboembolism 267
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry 266
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature 263
Breadth of complications of long-term oral anticoagulant care 255
Management of recurrent venous thromboembolism in cancer patients 253
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients 252
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal 251
24-hour blood pressare profile and left ventricular anatomy and function in untreated hypertensives with and without microalbuminuria 247
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. 246
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio. 246
Oral rivaroxaban for symptomatic venous thromboembolism 245
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis 244
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study 241
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study 241
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry 240
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data 239
Venous ischemic syndromes 239
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis 238
Prevention and treatment of venous thromboembolism 238
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome 238
Exaggerated initial response to warfarin following heart valve replacement 237
A new era for venous thromboembolism prevention in medical inpatients 237
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism 237
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice 237
Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: A randomized, controlled trial 236
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis. 234
A comparative study using thrombin generation and three different INR methods in patients on Vitamin K antagonist treatment 234
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty 231
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): An international, prospective, non-interventional study 231
Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy 231
Patient selection for thromboprophylaxis in medical inpatients 229
A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. 228
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. 228
Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study 227
Applying EBM in clinical practice 226
Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study 226
Venous and arterial thrombosis in patients with HIV infection 226
Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism: a systematic review and meta-analysis of the literature 226
Abdominal obesity and the risk of recurrent deep vein thrombosis. 225
Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients 225
Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review 225
A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. 224
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis 224
Anticoagulation After Stroke in Patients With Atrial Fibrillation: To Bridge or Not With Low-Molecular-Weight Heparin? 224
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree? 223
Statins, fibrates, and venous thromboembolism: a meta-analysis. 223
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis 222
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature 222
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS) 222
Duration of anticoagulation after venous thromboembolism in real world clinical practice 221
Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants 221
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable? 220
A survey of thromboprophylaxis management in patients with major trauma. 219
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: A multicenter cohort study 219
Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation 218
The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature 217
Acute myeloid leukemia with associated translocation t(15;17) and 11q23/MLL abnormality 216
Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes 216
Guidance for the management of venous thrombosis in unusual sites 216
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study 216
Venous thromboembolism: “…an ounce of prevention is worth a pound of cure” 216
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study 215
Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study. 215
Management of incidental splanchnic vein thrombosis in cancer patients 215
Venous thromboembolism: Past, present and future 215
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study 215
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: Beyond bleeding complications 215
Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study 214
Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study 214
Atypical case of Acute Coronary Syndrome due to Coronary-Pulmonary Steal Syndrome secondary to Pulmonary Embolism. 213
Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants 213
Direct oral anticoagulants in rare venous thrombosis 212
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism: An analysis of the randomised, double-blind HOKUSAI VTE trial 212
Managing challenging patients with venous thromboembolism: A practical, case-based approach 212
Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD 210
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation 209
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy 209
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE 208
Dabigatran in clinical practice: Contemporary overview of the evidence 208
Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema: The ALESSA Score Study 208
Clinical management of rivaroxaban-treated patients 207
Treating patients with cancer and acute venous thromboembolism 207
Totale 23.998
Salva come PNG Salva come JPEG
Categoria #
all - tutte 477.676
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 477.676
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.844 0 0 0 182 402 376 337 375 386 1.267 644 875
2022/20236.740 824 258 431 650 510 1.571 19 787 1.024 268 191 207
2023/202413.559 2.152 2.188 2.195 2.612 2.767 824 95 147 391 79 37 72
2024/20259.742 69 75 1.781 238 230 684 403 654 1.099 820 967 2.722
2025/202623.376 1.428 1.409 1.478 2.721 1.762 1.425 5.181 1.401 2.969 1.581 1.099 922
2026/20277.617 625 1.436 3.229 2.327 0 0 0 0 0 0 0 0
Totale 111.336